Literature DB >> 20595487

Use of statewide hospital discharge data to evaluate the economic burden of neurocysticercosis in Los Angeles County (1991-2008).

Curtis Croker1, Roshan Reporter, Laurene Mascola.   

Abstract

Statewide hospital discharge data were used to assess the economic burden of neurocysticercosis in Los Angeles County (LAC) from 1991 through 2008. A neurocysticercosis hospitalization was defined as having a discharge diagnosis of cysticercosis in addition to convulsions, seizures, hydrocephalus, cerebral edema or cerebral cysts. This study identified 3,937 neurocysticercosis hospitalizations, with the number of annual hospitalizations remaining relatively unchanged over the study period (R(2) = 0.01), averaging 219 per year (range 180-264). The total of all neurocysticercosis hospitalization charges over the study period was $136.2 million, averaging $7.9 million per year. The average charge per patient was $37.6 thousand and the most common payment method was Medicaid (43.9%), followed by private insurance (24.5%). The average length of stay was 7.2 days. The substantial number of hospitalizations and significant economic cost underscore the importance of neurocysticercosis in LAC.

Entities:  

Mesh:

Year:  2010        PMID: 20595487      PMCID: PMC2912585          DOI: 10.4269/ajtmh.2010.09-0494

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  13 in total

1.  Epidemiology of neurocysticercosis in Houston, Texas.

Authors:  Yazmin del la Garza; Edward A Graviss; Naval G Daver; Kimberley J Gambarin; Wayne X Shandera; Peter M Schantz; A Clinton White
Journal:  Am J Trop Med Hyg       Date:  2005-10       Impact factor: 2.345

2.  2006 National Hospital Discharge Survey.

Authors:  Carol J DeFrances; Christine A Lucas; Verita C Buie; Aleksandr Golosinskiy
Journal:  Natl Health Stat Report       Date:  2008-07-30

3.  An enzyme-linked immunoelectrotransfer blot assay and glycoprotein antigens for diagnosing human cysticercosis (Taenia solium).

Authors:  V C Tsang; J A Brand; A E Boyer
Journal:  J Infect Dis       Date:  1989-01       Impact factor: 5.226

4.  Development of a serologic assay to detect Taenia solium taeniasis.

Authors:  P P Wilkins; J C Allan; M Verastegui; M Acosta; A G Eason; H H Garcia; A E Gonzalez; R H Gilman; V C Tsang
Journal:  Am J Trop Med Hyg       Date:  1999-02       Impact factor: 2.345

5.  Sero-prevalence of Taenia solium cysticercosis and Taenia solium taeniasis in California, USA.

Authors:  C DeGiorgio; S Pietsch-Escueta; V Tsang; G Corral-Leyva; L Ng; M T Medina; S Astudillo; N Padilla; P Leyva; L Martinez; J Noh; M Levine; R del Villasenor; F Sorvillo
Journal:  Acta Neurol Scand       Date:  2005-02       Impact factor: 3.209

6.  Cysticercosis in Los Angeles County.

Authors:  F O Richards; P M Schantz; E Ruiz-Tiben; F J Sorvillo
Journal:  JAMA       Date:  1985-12-27       Impact factor: 56.272

7.  Cysticercosis surveillance: locally acquired and travel-related infections and detection of intestinal tapeworm carriers in Los Angeles County.

Authors:  F J Sorvillo; S H Waterman; F O Richards; P M Schantz
Journal:  Am J Trop Med Hyg       Date:  1992-09       Impact factor: 2.345

Review 8.  Neurocysticercosis. Two hundred thirty-eight cases from a California hospital.

Authors:  D Scharf
Journal:  Arch Neurol       Date:  1988-07

9.  Deaths from cysticercosis, United States.

Authors:  Frank J Sorvillo; Christopher DeGiorgio; Stephen H Waterman
Journal:  Emerg Infect Dis       Date:  2007-02       Impact factor: 6.883

10.  Spatial distribution of Taenia solium porcine cysticercosis within a rural area of Mexico.

Authors:  Julio Morales; José Juan Martínez; Marcos Rosetti; Agnes Fleury; Victor Maza; Marisela Hernandez; Nelly Villalobos; Gladis Fragoso; Aline S de Aluja; Carlos Larralde; Edda Sciutto
Journal:  PLoS Negl Trop Dis       Date:  2008-09-03
View more
  16 in total

Review 1.  Under seize: neurocysticercosis in an immigrant woman and review of a growing neglected disease.

Authors:  Meredith Bock; Hector H Garcia; Peter Chin-Hong; Sanjiv M Baxi
Journal:  BMJ Case Rep       Date:  2015-12-18

Review 2.  Diagnosis and treatment of neurocysticercosis.

Authors:  Theodore E Nash; Hector H Garcia
Journal:  Nat Rev Neurol       Date:  2011-09-13       Impact factor: 42.937

3.  Neurocysticercosis in the United States.

Authors:  Jose A Serpa; A Clinton White
Journal:  Pathog Glob Health       Date:  2012-09       Impact factor: 2.894

Review 4.  Clinical manifestations, diagnosis, and treatment of neurocysticercosis.

Authors:  Julio Sotelo
Journal:  Curr Neurol Neurosci Rep       Date:  2011-12       Impact factor: 5.081

5.  Survey of Obstetrician-Gynecologists in the United States About Taeniasis and Cysticercosis.

Authors:  Rebecca L Hall; Britta Anderson; Jay Schulkin; Paul T Cantey; Susan P Montgomery; Jeffrey L Jones
Journal:  Am J Trop Med Hyg       Date:  2016-11-14       Impact factor: 2.345

6.  Cysticercosis-related hospitalizations in the United States, 1998-2011.

Authors:  Kaitlin A O'Keefe; Mark L Eberhard; Shira C Shafir; Patricia Wilkins; Lawrence R Ash; Frank J Sorvillo
Journal:  Am J Trop Med Hyg       Date:  2014-11-10       Impact factor: 2.345

Review 7.  Immunology of Taenia solium taeniasis and human cysticercosis.

Authors:  H H Garcia; S Rodriguez; J S Friedland
Journal:  Parasite Immunol       Date:  2014-08       Impact factor: 2.280

Review 8.  Diagnostic criteria for neurocysticercosis, revisited.

Authors:  Oscar H Del Brutto
Journal:  Pathog Glob Health       Date:  2012-09       Impact factor: 2.894

9.  Taenia solium Tapeworm Infection, Oregon, 2006-2009.

Authors:  Seth O'Neal; John Noh; Patricia Wilkins; William Keene; William Lambert; James Anderson; Jennifer Compton Luman; John Townes
Journal:  Emerg Infect Dis       Date:  2011-06       Impact factor: 6.883

10.  The impact of neurocysticercosis in california: a review of hospitalized cases.

Authors:  Curtis Croker; Matthew Redelings; Roshan Reporter; Frank Sorvillo; Laurene Mascola; Patricia Wilkins
Journal:  PLoS Negl Trop Dis       Date:  2012-01-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.